List of Apriso drug patents

Apriso is owned by Valeant Pharms Intl.

Apriso contains Mesalamine.

Apriso has a total of 1 drug patent out of which 0 drug patents have expired.

Apriso was authorised for market use on 31 October, 2008.

Apriso is available in capsule, extended release;oral dosage forms.

Apriso can be used as for the maintenance of remission of ulcerative colitis.

The generics of Apriso are possible to be released after 01 May, 2030.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8865688 VALEANT PHARMS INTL Compositions and methods for treatment of bowel diseases with granulated mesalamine
May, 2030

(7 years from now)

Drugs and Companies using MESALAMINE ingredient

Market Authorisation Date: 31 October, 2008

Treatment: For the maintenance of remission of ulcerative colitis

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of APRISO before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in